Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;19(1):4-12.
doi: 10.4103/0974-9233.92110.

Diabetic macular edema: current and emerging therapies

Adam S Wenick  1 , Neil M Bressler
Affiliations

Diabetic macular edema: current and emerging therapies

Adam S Wenick et al. Middle East Afr J Ophthalmol. 2012 Jan.

Abstract

Diabetic macular edema is a leading cause of vision impairment among people within the working- age population. This review discusses the pathogenesis of diabetic macular edema and the treatment options currently available for the treatment of diabetic macular edema, including for focal/grid photocoagulation, intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor agents. The biologic rationale for novel therapeutic agents, many of which are currently being evaluated in clinical trials, also is reviewed.

Keywords: Diabetic Macular Edema; Focal/Grid Photocoagulation; Intravitreal Corticosteroids.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. World Health Organization Diabetes Fact Sheet Number 312. [cited in 2011]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
    1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998–1003. - PubMed
    1. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105:1801–15. - PubMed
    1. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647–61. - PubMed
    1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: Pathogenesis and treatment. Surv Ophthalmol. 2009;54:1–32. - PubMed